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ypertension is a major public health concern be-
cause it increases the risk of stroke, myocardial 
infarction, and congestive heart failure.1,2 Despite 
improved treatment modalities, a substantial number of 
patients with hypertension are refractory to medical inter-
vention.2 Apart from well-known mechanisms that explain 
refractory hypertension, another potential contributing mech-
anism may be augmented sympathetic activity.3–5 Several 
studies have shown that, despite adequate blood-pressure 
(BP)-lowering therapy, the increased central sympathetic 
tone persists.6 Maybe more importantly, it has been sug-
gested that increased sympathetic activity itself may play an 
additional pathophysiological role in the development of 
cardiovascular complications.7,8
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In animal studies 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors (statins) have been shown 
to reduce renal sympathetic nerve traffic.9 In stroke-prone 
spontaneously hypertensive rats, atorvastatin reduced systolic 
BP (SBP) and urinary norepinephrine excretion.10 Szramka 
et al showed a sympathoinhibitory effect of atorvastatin in 
coronary artery disease (CAD) patients.11 To date, the under-
lying mechanism by which statins reduce sympathetic outflow 
has not been elucidated. An effect on central nitric oxide (NO) 
and reactive oxygen species (ROS) formation, as well as regu-
lation of the AT1-receptor expression, have been proposed as 
possible explanations.12–14
We hypothesized that, as sympathoexcitation is a clear 
feature of primary hypertension, administration of a statin 
to hypertensive patients will reduce sympathetic nervous 
system activity.
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Sympathoinhibition by Atorvastatin  
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Paul Smits, MD, PhD; Jacques W.M. Lenders, MD, PhD
Background:  Experimental animal data suggest that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors (statins) might reduce enhanced sympathetic activity, a hallmark of hypertensive patients. This 
hypothesis was tested for the first time in patients with primary hypertension.
Methods and Results:  Using a prospective, randomized, placebo-controlled, double-blind, cross-over design, 
a proof-of-principle  trial was performed  in 13 patients with mild  to moderate primary hypertension, who were 
randomly assigned to a regimen of atorvastatin (80 mg/day) for 3 weeks, followed by placebo for 3 weeks or to 
a regimen of placebo for 3 weeks, followed by atorvastatin (80 mg/day) for 3 weeks. Microneurography was used 
at the end of each treatment period to measure sympathetic nervous system activity (muscle sympathetic nerve 
activity: MSNA). Heart  rate  variability  (HRV)  and  plasma  norepinephrine  concentrations were  also measured. 
Additionally, effects on blood pressure (BP) and heart rate (HR) were assessed by 24-h ambulatory BP mea-
surement.  Atorvastatin  reduced  postganglionic  MSNA  (atorvastatin  35.0±2.0  vs  placebo:  39.2±1.5 bursts/min, 
P=0.008)  and  heart  frequency  corrected MSNA  (atorvastatin:  58.5±2.0  vs  placebo:  64.7±3.0 bursts/100 beats, 
P=0.02). Atorvastatin had no significant effect on plasma norepinephrine levels, HRV, BP or HR.
Conclusions:  In patients with mild to moderate hypertension, atorvastatin reduces postganglionic MSNA, which 
supports the hypothesis that HMG-CoA reductase plays a role in sympathetic nervous system activity.    (Circ J 
2010; 74: 2622 – 2626)
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Methods
Participants
We included 13 patients with primary hypertension were a 
proof-of-principle trial. Inclusion criteria were: age 18–70 
years, a body mass index (BMI) 18–35 kg/m2, and a history of 
mild to moderate hypertension (defined as average awake SBP 
between 140 and 179 mmHg, or diastolic BP between 90 and 
109 mmHg). Secondary hypertension was excluded according 
to standard clinical criteria. If treated with antihypertensive 
drugs, the drug regimen had to be stable for 2 months. Sub-
jects were excluded from the study if they had suffered a car-
diovascular event within the past 6 months, had renal disease 
(plasma creatinine concentrations >120 μmol/L for females or 
>133 μmol/L for males, albuminuria >300 mg/day), diabetes, 
or any other severe medical condition. The institutional review 
committee approved the study and written informed consent 
was given by all patients before participation in the study.
Study Protocol
Using a prospective, double-blind, cross-over design, pa-
tients were randomly assigned to a regimen of atorvastatin 
(80 mg/day) for 3 weeks, followed by placebo for 3 weeks or 
to a regimen of placebo for 3 weeks, followed by atorvastatin 
(80 mg/day) for 3 weeks. If patients were already using statins, 
they were included in the study after a washout period of 
2 weeks (n=4). At the end of each treatment period (atorvas-
tatin or placebo) measurements were performed. Muscle 
sympathetic nervous system activity (MSNA) was assessed 
by microneurography of the peroneal nerve. In addition, heart 
rate variability (HRV) and venous plasma catecholamine 
concentrations were determined. Prior to each visit, ambula-
tory 24-h BP monitoring was performed. Experiments were 
conducted at 8.00 am after an overnight (10-h) fast and with 
the patient lying supine in a quiet temperature-controlled 
room (23–24°C). Subjects had to abstain from caffeine, tea, 
alcohol, chocolates and smoking for at least 12 h prior to the 
test procedure. All experiments were carried out after voiding 
to prevent reflex sympathoexcitation. After complete instru-
mentation, 30 min of rest were included, then HRV measure-
ment was performed for 10 min. Finally, blood samples were 
drawn and microneurography was performed.
Measurement of Sympathetic Activity
Multiunit postganglionic sympathetic nerve traffic was re-
corded using microneurography of the peroneal nerve at the 
fibular head.15,16 All measurements were performed by the 
same investigator (M.E.G.). The peroneal nerve was located 
using an electrical probe delivering transdermal electrical 
impulses (40–60 mV, 0.2 ms, 1 Hz). Next, a sterile Tungsten 
microelectrode was inserted percutaneously in the under-
lying peroneal nerve posterior to the fibular head. Multiunit 
MSNA bursts were obtained as the average voltage after 
filtering (bandwidth 700–2,000 Hz) and integrating (time con-
stant 0.1 s). MSNA registration is defined as optimal when: 
(a) electrical stimulus induces muscle twitches, without con-
comitant paresthesia, (b) stretching of the appropriate mus-
cle elicits afferent, mechanoreceptive activity, without the 
occurrence of mechanoreceptive afferent signals after gentle 
touch or pressure within the cutaneous receptive field of the 
nerve (if paresthesia is provoked, without concomitant muscle 
twitch or mechanoreceptive afferent signals are recorded after 
touch or pressure, sympathetic skin nerve activity is mea-
sured, but this lies outside the scope of our study), and (c) 
MSNA occurs in bursts strictly bound to the cardiac rhythm, 
and increases in frequency and amplitude during Vasalva 
maneuver. To quantify the frequency of MSNA bursts, only 
bursts with a signal to noise ratio ≥3 were included.17,18 
Bursts were identified using an automated computer program 
with preset parameters to exclude observer bias. A preset 
triangle with a base of 0.8 s, correlated to the known delay 
between the R-peak on electrocardiogram (ECG) and the 
postganglionic burst, was used to scan the MSNA signal and 
identify sympathetic bursts. Maximal and average amplitudes 
were calculated and potential bursts were correlated to a 
percentage of the maximal amplitude. The computer-derived 
measures were visually confirmed by the investigator to iden-
tify and exclude noise artefacts. Microneurography record-
ings were quantified as bursts per 100 beats, which has a 
high intra-individual reproducibility, and bursts per minute.19
Laboratory Determinations
Fasting total cholesterol (TC), high-density lipoprotein (HDL) 
and triglyceride (TG) levels were measured at the end of each 
treatment period by automated enzymatic methods. Low-
density lipoprotein cholesterol (LDL-C) was calculated using 
the Friedewald equation. For detecting potential statin side-
effects, plasma liver enzymes and creatine kinase levels 
were measured at each visit (baseline, 3 and 6 weeks).
Plasma catecholamine concentrations were measured 
using high-performance liquid pressure analysis and fluoro-
metric detection.20 Within- and between-run coefficients of 
variation for plasma epinephrine were 4.1% and 8.1% at a 
level of 0.166 nmol/L and for norepinephrine, 4.1% and 6.1% 
at a level of 1.76 nmol/L, respectively. Analytical detection 
limits were 0.003 and 0.002 nmol/L for epinephrine and nor-
epinephrine, respectively. Catecholamines were collected in 
ice-chilled 10-ml Vacutainer tubes (Becton-Dickenson Co, 
Franklin Lakes, NJ, USA) containing 0.2 ml of a solution of 
EGTA (0.25 mol/L) and gluthatione (0.20 mol/L).
HRV
Using a 2-channel Holter (Medilog 4500-3, Oxford Instruments 
Ltd, UK) a 10-min ECG was recorded for each patient at each 
visit. Ectopic beats and arrhythmias were excluded using the 
Oxford scanning software (version 6.0). R–R interval selec-
tion was performed using a beat-to-beat filter set at N-N-N, 
whereby the interval being considered should start and end 
in a “normal” beat and so should the preceding R–R inter-
val. Rejected intervals were interpolated over the invalid 
area. Before converting the interval tachogram to frequency 
domain analyses, the mean R–R interval was calculated from 
the tachogram and subtracted from each R–R interval to 
reduce spectral leakage. A fast Fourier transformation was 
performed from the interpolated tachogram resampled at 
292 ms, using the Oxford spectral analysis software package. 
Results from the 10-min interval were averaged to form a 
composite spectrum. Total power between 0.003 and 0.40 Hz 
was calculated to represent the total variance for a 10-min 
interval. Power was quantified as total power, high frequency 
(HF: 0.15–0.40 Hz) and low frequency (LF: 0.04–0.15 Hz). 
HF represents the parasympathetic contribution to the spec-
trum, whereas LF represents a combination of parasympa-
thetic and sympathetic influences.21 The LF/HF ratio is a 
measure of autonomic balance, with an increasing ratio rep-
resenting sympathetic predominance.
24-h Ambulatory BP Measurement
Prior to each experiment, a validated 24-h indirect BP moni-
tor (Mobil-O-Graph CE0434, Firmware version 12, I.E.M. 
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Industrielle Entwicklung Medizintechnik GmbH, Stolberg, 
Germany) was connected to each patient.
Statistical Analysis
Data are expressed as mean ± SEM unless indicated other-
wise. Differences between measurements performed during 
atorvastatin administration or placebo were assessed using 
parametric (Student’s t-test for paired observations) or non-
parametric (paired Wilcoxon) tests as appropriate. A power 
calculation assuming a basal sympathetic activity of 60± 
15 bursts/100 beats, revealed that in order to detect a dif-
ference of 25% in burst frequency with a power of 80% at 
a significance level of 0.05 (α), 11 subjects needed to be 
included. Allowing for a dropout and failure rate of micro-
neurography of 20%, 13 patients needed to be included. A 
2-tailed P-value <0.05 was considered to be statistically sig-
nificant. Correlations between parameters were calculated 
using Pearson correlation coefficients.
Results
Table 1 presents the baseline characteristics of the study 
population. At entry, 10 of the 13 patients had BP >130 mmHg 
systolic or 80 mmHg diastolic. Only 1 patient was not on anti-
hypertensive medication. The baseline medications remained 
unchanged throughout the course of the study. All patients 
completed the study but in 1 patient a MSNA measure-
ment failed because of technical problems, so paired MSNA 
recordings were available in 12 of the 13 patients. There 
were no significant differences in the baseline characteristics 
of the groups of patients with regard to the sequence of ator-
vastatin or placebo.
Atorvastatin reduced the plasma TC and LDL-C levels in 
all patients (TC: from 5.4±0.3 to 3.5±0.2 mmol/L, P<0.001; 
LDL cholesterol: from 3.3±0.3 to 1.7±0.2 mmol/L, P<0.001). 
The HDL-cholesterol and TG levels were not significantly 
altered.
MSNA was significantly lower during atorvastatin 80 mg 
compared with placebo (Figure 1) (total MSNA, atorvas-
tatin: 35.0±2.0 vs placebo: 39.2±1.5 bursts/min, P=0.008; fre-
quency-corrected MSNA: atorvastatin: 58.5±2.0 vs placebo: 
64.7±3.0 bursts/100 beats, P=0.02). Although the MSNA 
values positively correlated with plasma cholesterol levels 
(all measurements combined, r=0.50, P=0.01, Figure 2), the 
reduction in MSNA was independent of the degree of change 
in plasma cholesterol levels (r=0.24, P=0.45) and did not cor-
relate with the change in LDL-C levels (r=−0.22, P=0.51). 
This finding suggests that the effect was caused by atorvas-
tatin itself, instead of the change in cholesterol level. The 
atorvastatin effect on MSNA was independent of baseline BP, 
Table 1. Baseline Characteristics of the Patients With Primary 
Hypertension
Age (years) 54±16
Sex (M/F) 9/4
BMI (kg/m2) 26.7±1.0　
SBP (mmHg) 152±12　
DBP (mmHg) 92±3　
HR (beats/min) 71±3　
Concomitant medication (n)
   β-blockers 7
    Aspirin 3
    Diuretics 7
    Calcium antagonist 8
    ACEI/ARB 8
    Statin 4
Data are mean ± SD.
BMI, body mass index; SBP, systolic blood pressure (BP); DBP, 
diastolic BP; HR, heart rate; ACEI, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin-receptor blocker.
Figure 1.    Individual  levels  of  muscle  sympathetic  nerve   
activity (MSNA) inthe hypertensive patients (bursts/100 heart 
beats  and  bursts/min  for  total MSNA)  during  placebo  (A) 
and atorvastatin (B) administration.
Figure 2.    Relationship between muscle sympathetic nerve 
activity (MSNA) and plasma total cholesterol levels. The Pear-
son  correlation  coefficient  is  0.50  (P=0.01).  (Blue) Atorvas-
tatin, (red) placebo.
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heart rate (HR), age and BMI. Plasma concentrations of nor-
epinephrine (atorvastatin: 2.7±0.4 vs placebo: 2.4±0.2 nmol/L) 
and epinephrine (atorvastatin: 0.16±0.03 vs placebo: 0.15± 
0.03 nmol/L) were similar during atorvastatin and during 
placebo. Day-time and night-time systolic and diastolic BPs, 
as assessed by 24-h ambulatory BP measurement, were not 
significantly different between atorvastatin and placebo 
(Table 2). There was no difference in HRV between atorv-
astatin and placebo (Table 3).
Discussion
The results of this study provide evidence that a high dose of 
atorvastatin produces a significant reduction in post-gangli-
onic sympathetic nerve activity in patients with primary 
hypertension. Our conclusion is based on the finding of a 
nearly 9% lower MSNA with atorvastatin treatment com-
pared with placebo. The lower MSNA levels did not trans-
late into lower venous plasma norepinephrine levels or lower 
BP, or in a change in HRV.
The reduction in MSNA seemed to be related to the use of 
atorvastatin and not to the reduction in plasma cholesterol, 
but our study is too small to draw conclusions on this point.
The results of the present study are in line with earlier 
findings in animal experimental models. Kishi et al observed 
a significant reduction in 24-h urinary norepinephrine con-
centrations after treating stroke-prone spontaneous hyperten-
sive rats for 30 days with atorvastatin.10 Pliquette et al dem-
onstrated a significant reduction in renal sympathetic activity 
and plasma norepinephrine levels when treating rabbits with 
heart failure with simvastatin.9 The hypothetical concept that 
underlies those findings is that statins downregulate mRNA 
and protein expression of the angiotensin II type 1 receptor 
and NAD(P)H oxidase subunits, and inhibit NAD(P)H oxi-
dase activity in the rostral ventrolateral medulla.12 The subse-
quent decline in formation of ROS, a well-known stimulator 
of sympathetic activity, results in reduced sympathetic out-
flow. In addition, statins enhance NO synthesis in areas related 
to integration of sympathetic activity and because NO sup-
presses central sympathetic outflow, the resulting effect of 
statins is sympathoinhibition.
Up till now, only a few studies have assessed the effects 
of statins on sympathetic activity in humans and most have 
focused on catecholamine levels and HRV, which are sur-
rogate indices of sympathetic activity and subject to large 
intraindividual variation. To our knowledge, only one study 
has used microneurography to directly measure changes in 
post-ganglionic sympathetic nerve activity after treatment 
with atorvastatin.22 Those authors also found a significant 
reduction in MSNA after 8 weeks of treatment with atorvas-
tatin. However, in that study a parallel group design was used, 
comparing 10 hypertensive patients with 8 healthy controls 
and only the hypertensive patients received atorvastatin. In 
our study, we used a randomized, placebo-controlled, double-
blind, cross-over design, which has stronger statistical power.
The finding that the reduction in MSNA after adminis-
tering atorvastatin 80 mg was not translated into a change in 
plasma norepinephrine levels is not completely unexpected. 
First, the plasma norepinephrine level is a global marker of 
noradrenergic sympathetic tone. The plasma norepinephrine 
level is the net result of neuronal release and clearance of 
norepinephrine, so it is possible that a reduced neuronal 
release of norepinephrine is masked if there is also a reduced 
clearance. An alternative explanation is that the MSNA 
results refer only to sympathetic activity in the skeletal mus-
cle compartment whereas the plasma norepinephrine level is 
the result of all vascular beds. Indeed, it is well established 
that there are significant regional differences in sympathetic 
activity.23 Finally, there might be a dose – effect relationship 
for the effect of statins on plasma norepinephrine levels and 
this explanation is supported by a previous study in animals.24 
In rabbits with pacing-induced chronic heart failure (CHF), 
plasma norepinephrine levels were only reduced when admin-
istering a simvastatin dose up to 3 mg · kg–1 · day–1, whereas 
the effects on MSNA were already found at much lower 
doses.9 The 3 mg · kg–1 · day–1 dose in rabbits exceeds by far 
the usual dose (eg, simvastatin 40 mg once daily) in human 
subjects.
Several studies have shown that statins are able to sig-
nificantly reduce BP in hypertensive patients.25,26 There are 
several possible reasons why this effect did not occur in the 
current study. First, the sympathoinhibitory effect of the 
dose of atorvastatin might not have been large enough to be 
translated into a significant decrease in BP or HR. Even a 
simvastatin dose as high as 3 mg · kg–1 · day–1 did not affect 
the hemodynamics in the CHF rabbits, although RSNA was 
reduced.9 In accordance with the findings from that animal 
study and our current study, atorvastatin 80 mg administered 
to CAD patients had no effect on BP, despite a significant 
reduction in plasma norepinephrine levels.11 Second, it is 
possible that our study population was not large enough to 
uncover a decrease in BP. In addition, our patients were only 
treated and observed for a short period of time. Therefore, 
our study can not exclude that statins do reduce BP in the 
long term. Finally, noncompliance with statin administration 
might be an explanation but the decrease in plasma TC and 
LDL-C levels in all patients argues against this possibility.
Study Limitations
Several potential limitations should be discussed. All but 
1 patient were on antihypertensive treatments. Although this 
might interfere with the statin, it is unlikely to have con-
Table 2. 24-h Ambulatory BP During Atorvastatin and Placebo 
Administration to Patients With Primary 
Hypertension
Atorvastatin Placebo
Day Night Day Night
SBP (mmHg) 139±3 130±4 143±5 133±5
DBP (mmHg)   89±3   83±4   90±3   83±3
MAP (mmHg) 105±3   98±4 107±3   98±4
HR (beats/min)   81±5   68±5   78±4   62±4
Data are mean±SEM.
MAP, mean arterial BP. Other abbreviations see in Table 1.
Table 3. HR Variability During Atorvastatin and Placebo 
Administration to Patients With Primary 
Hypertension
Atorvastatin Placebo
LF (ms2) 1,480±736　 1,513±729　
HF (ms2) 711±248 532±136
LF/HF 1.84±0.37 2.97±0.97
Total PSD (ms2) 5,090±1,473 4,579±1,830
LF, low-frequency power; HF, high-frequency power; LF/HF, low-
frequency/high-frequency  ratio;  PSD,  power  spectral  density. 
Other abbreviation see in Table 1.
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founded the results because all patients remained on the same 
medications, during both atorvastatin and placebo adminis-
tration. Our study encompasses a relatively small group of 
subjects, but because of the cross-over design it was ade-
quately powered for the assessment of MSNA.
Although it is difficult to dissect the contribution of atorv-
astatin itself from the reduction in LDL-C to sympathoinhi-
bition, there was no indication that the degree of reduction in 
LDL-C correlated with the MSNA effect, thus favouring but 
not proving a pleiotropic effect of atorvastatin.
It is too premature to state that the findings of the present 
study have clinical implications. Although the decrease in 
sympathetic activity did not result in a change in BP or nor-
epinephrine concentration, this does not mean that this find-
ing has no clinical relevance. High sympathetic tone has been 
associated with insulin resistance, metabolic effects and 
reduced skeletal muscle perfusion.27–29 All of these effects are 
mainly α-adrenergic mediated and were not assessed in this 
study. Patients with hypertension frequently have increased 
plasma lipids and are treated with statins. If statins indeed 
lower sympathetic activity, this might, apart from their effects 
on plasma lipids, contribute to their beneficial cardiovascu-
lar effects in the long term.30
In conclusion, the present study shows a small but signifi-
cant reduction in sympathetic nerve traffic after short-term 
atorvastatin administration in patients with primary hyper-
tension. Although these findings need confirmation in larger 
groups of patients, they do suggest an additional beneficial 
mechanism by which statins reduce cardiovascular compli-
cations.
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